Dr Mark Kris continues his discussion on neoadjuvant vs adjuvant therapy for locally advanced lung cancer, offering his take ...
MedPage Today on MSN
Adjuvant RT to Thwart Bladder Cancer Recurrence 'Knocked It Out of the Park'
The 2-year local recurrence-free survival (LRFS) improved from 76.0% without adjuvant RT to 87.1% with it. Disease-free (DFS), bladder cancer-specific (BCSS), and overall survival (OS) all had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback